Pharmaceutical composition for preventing or treating hyperlipidemia

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9724336
APP PUB NO 20140336229A1
SERIAL NO

14361371

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Provided is a pharmaceutical composition for preventing or treating hyperlipidemia comprising (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methyl)-4-methyl-1,3-oxazolidin-2-one or its pharmaceutically acceptable salt; and an angiotensin II receptor blocker as active ingredients.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
DAEWOONG PHARMACEUTICAL CO LTD35-14 JEYAKGONGDAN 4-GIL HYANGNAM-EUP HWASEONG-SI GYEONGGI-DO 18623

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Koh, Eun-Ji Gyeonggi-do, KR 2 0
Lee, Jong-Wook Gyeonggi-do, KR 107 2132
Lee, Sang-Ho Gyeonggi-do, KR 190 1813
Lim, Taek-Joo Seoul, KR 2 0

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Feb 8, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 8, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00